Cellectar presented data from its ongoing phase 2 clover-1 study of iopofosine i-131 at the 63rd ash annual meeting and exposition

Poster highlighted data from 11 patients with at least triple class refractory multiple myeloma
CLRB Ratings Summary
CLRB Quant Ranking